Awareness and Preparedness in the Diabetes Glucagon Market during Q1 2026 

Novo Nordisk emphasized partnerships to advance diabetes and obesity treatments and improve US affordability, alongside awareness efforts, while also communicating the discontinuation of Zegalogue and directing HCPs to alternative therapies.

Viatris focused on innovation and global care delivery through digital engagement and storytelling, highlighting disease prevention in rural settings.

Xeris reinforced hypoglycemia awareness and emergency preparedness, emphasizing the ease of use of a ready-to-use glucagon option.